Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Market maker working hard

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Dec 23, 2020 3:58pm

196 Views

Post# 32171703

RE:Market maker working hard

3burtc wrote: To get your shares! Btw what was was the point of going from the venture to the tsx, just to have the same garbage trades? Anyway have a very merry Christmas EVERYONE!

It isn't about one specific move ... it's all required.
In the end, the order of operations really shouldn't matter.
It will get us to the right place.

IMO

Merry Chrstmas !

<< Previous

Bullboard Posts

Next >>

@ the Bell: TSX advances to start off Christmas trading week